Whilst SGLT2i have consistently shown effectiveness in the treatment of PI3K inhibitor-associated hyperglycemia, there have also been multiple case reports of diabetic ketoacidosis in the context of PI3K inhibitor use, both with and without SGLT2i usage, and thus the use of SGLT2i in this setting must be with caution (9). This evidence concerns the gene PIK3CA and diabetic ketoacidosis.